$Chimerix (CMRX.US)$Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Benzinga· 1 min ago Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
$Chimerix (CMRX.US)$ Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Monday, 9th December at 4:01 pm Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
$T2 Biosystems (TTOO.US)$T2 Biosystems Announces Plans to License Its Proprietary Technology to Expand Its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens GlobeNewswire· 6 mins ago Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the "Company"), a leader in the rapid detection o...
$Tonix Pharmaceuticals (TNXP.US)$ Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Positive Fast Track designation received from FDA, expediting the review process Significant positive results in Phase 3 RESILIENT trial with p-value of 0.00005 Addressing $2.8 billion market expected to grow to $4.13 billion by 2032 Potential to be first new fibromyalgia drug in over 15 years Negative None.
Benzinga· 1 min ago
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma
Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA
Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Monday, 9th December at 4:01 pm
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma
Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA
Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
GlobeNewswire· 6 mins ago
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream
LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the "Company"), a leader in the rapid detection o...
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
Positive
Fast Track designation received from FDA, expediting the review process
Significant positive results in Phase 3 RESILIENT trial with p-value of 0.00005
Addressing $2.8 billion market expected to grow to $4.13 billion by 2032
Potential to be first new fibromyalgia drug in over 15 years
Negative
None.
No comment yet